research

CORE ONE LABS’ AKOME SEEKS TO REVOLUTIONIZE TREATMENT OF PARKINSON’S DISEASE AND SUBMITS APPLICATION TO PROTECT IP

Ayahuasca, Parkinson's Disease, Pre-PD /

Akome’s AKO004 psychedelic drug formulation, for use in the treatment of Parkinson’s disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive.  Initial data analysis indicates that the AKO004 composition is safe and efficacious for use, and presents many positive properties which may counter or mitigate neurodegeneration […]

CORE ONE LABS’ AKOME SEEKS TO REVOLUTIONIZE TREATMENT OF PARKINSON’S DISEASE AND SUBMITS APPLICATION TO PROTECT IP Read More »

Oral, nasal, and gut microbiota in Parkinson’s disease

Gut Dysbiosis, Gut Microbiota, Metabolites, Oral Microbiome /

Parkinson’s disease (PD) is the second most frequently diagnosed neurodegenerative disease. The purpose of this study was to investigate the link between microbiota composition in important mucosal interfaces (oral, nasal, and intestinal) and PD. Sequencing was undertaken of the V4–V5 region of the 16S ribosomal RNA (rRNA) gene of the microbiome from the oral cavity,

Oral, nasal, and gut microbiota in Parkinson’s disease Read More »

Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions

A-Synuclein, Endotoxin, Parkinson's Disease, Pre-PD /

Thoughts – Just maybe we are finding the mechanics behind the 2+ theory of PD which states that 2 or more variables must come about in order PD to progress into diagnosisable PD. Protein aggregates associated with neurodegenerative diseases have the ability to transmit to unaffected cells, thereby templating their own aberrant conformation onto soluble

Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions Read More »

PROTECTIVE ROLE OF THE FLANKING DOMAINS AND MEMBRANE SELECTIVITY IN THE ALPHA-SYNUCLEIN

A-Synuclein, Parkinson's Disease /

Alpha-synuclein protein is associated with Parkinson’s disease and is an intrinsically disordered protein (IDP) in solution. The protein consists of three domains: N-terminal domain, NAC domain, and C-terminal domain. In this research, I used the Gaussian accelerated Molecular Dynamics (GaMD) simulations to examine the role of the flanking domains of the protein. My data show

PROTECTIVE ROLE OF THE FLANKING DOMAINS AND MEMBRANE SELECTIVITY IN THE ALPHA-SYNUCLEIN Read More »

Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer’s disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis

Probiotics, Prebiotics and Symbiotics /

According to recent evidence, psychobiotics exert beneficial effects on central nervous system-related diseases, such as mental disorders. Lactobacillus plantarum PS128 (PS128), a novel psychobiotic strain, improves motor function, depression, and anxiety behaviors. However, the psychobiotic effects and mechanisms of PS128 in Alzheimer’s disease (AD) remain to be explored. Objectives The goal of the current study was to

Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer’s disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis Read More »

A novel multi-target strategy to attenuate the progression of Parkinson’s disease by diamine hybrid AGE/ALE inhibitor

A-Synuclein, Parkinson's Disease, Pre-PD /

Instead of a conventional ‘one-drug-one-target approach’, this article presents a novel multi-target approach with a concept of trapping simultaneously as many detrimental factors as possible involved in the progression of Parkinson’s disease. These factors include reactive carbonyl species, reactive oxygen species, Fe3+/Cu2+ and ortho-quinones (o-quinone), in particular. Different from the known multi-target strategies for Parkinson’s disease,

A novel multi-target strategy to attenuate the progression of Parkinson’s disease by diamine hybrid AGE/ALE inhibitor Read More »

Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion

Butyrate, Gut Dysbiosis, Gut Microbiota, Short Chain Fatty Acids /

Emerging evidence is revealing that alterations in gut microbiota are associated with colorectal cancer (CRC). However, very little is currently known about whether and how gut microbiota alterations are causally associated with CRC development. Here we show that 12 faecal bacterial taxa are enriched in CRC patients in two independent cohort studies. Among them, 2 Porphyromonas species

Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion Read More »

Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson’s disease patients

Parkinson's Disease, Pre-PD, Vitamins / Supplements / Nutraceuticals /

There is sufficient evidence to support vitamin D’s noncalcemic effects and the role ofvitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluatewhether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects(HS), multiple system atrophy (MSA) and Parkinson’s disease (PD)

Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson’s disease patients Read More »

Mitochondrial Dysfunction in a Mouse Model of Prodromal Parkinson’s Disease: A Metabolomic Analysis

Biomarkers, Mitochondria, Parkinson's Disease, Pre-PD /

For the development of disease-modifying therapies for Parkinson’s disease (PD) the identification of biomarkers in the prodromal stage is urgently required. Because PD is considered a systemic disease even in the early stage, we performed a metabolomic analysis of the plasma from a mouse model of prodromal PD (p-PD). Increased levels of isobutyrylcarnitine in p-PD

Mitochondrial Dysfunction in a Mouse Model of Prodromal Parkinson’s Disease: A Metabolomic Analysis Read More »